RBC Capital maintains Pennant Group at 'outperform' with a price target of $14.00 May 9, 2023 Comments are off
RBC Capital maintains Taskus at 'outperform' with a price target of $21.00 May 9, 2023 Comments are off
RBC Capital maintains Viracta Therapeutics at 'outperform' with a price target of $7.00 May 9, 2023 Comments are off
MultiPlan Corp. Acquires Leading Healthcare Data and Analytics Firm Benefits Science LLC May 9, 2023 Comments are off
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 May 9, 2023 Comments are off
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination May 9, 2023 Comments are off